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Abstract
Background—Adjunctive behavioral smoking cessation treatments have the potential to improve 
outcomes beyond standard care. The present study had two aims: 1) compare standard care (SC) 
for smoking (four weeks of brief counseling and monitoring) to SC plus prize-based contingency 
management (CM), involving the chance to earn prizes on days with demonstrated smoking 
abstinence (carbon monoxide (CO) ≤6ppm); and 2) compare the relative efficacy of two prize 
reinforcement schedules - one a traditional CM schedule, and the second an early enhanced CM 
schedule providing greater reinforcement magnitude in the initial week of treatment but equal 
overall reinforcement.
Methods—Participants (N = 81 nicotine-dependent cigarette smokers) were randomly assigned 
to one of the three conditions.
Results—Prize CM resulted in significant reductions in cigarette smoking relative to SC. These 
reductions were not apparent at follow-up. We found no meaningful differences between the 
traditional and enhanced CM conditions.
Conclusions—Our findings reveal that prize CM leads to significant reductions in smoking 
during treatment relative to a control intervention, but the benefits did not extend long-term.
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1. INTRODUCTION
Cigarette smoking results in 1 of every 5 deaths and extraordinary economic costs (Centers 
for Disease Control and Prevention, 2008). Contingency management (CM) has 
demonstrated efficacy for treating substance use disorders (Dutra et al., 2008; Prendergast et 
al., 2006), including smoking (Ledgerwood, 2008 review). However, CM can be costly, with 
reinforcement exceeding $1,000 (Higgins et al., 2004; Lamb et al., 2004). Petry and 
colleagues developed a prize reinforcement program lower-cost by design, with 
demonstrated efficacy with cocaine, opioid, alcohol and poly-substance-dependent patients 
(e.g., Peirce et al., 2006; Petry et al., 2000; Petry et al., 2012). To date, one small, non-
randomized pilot has examined prize CM for smoking among substance abuse patients, with 
prize CM engendering greater proportions of negative CO tests than standard care (Alessi et 
al., 2008). The present study examines the efficacy of Prize CM for smoking in a 
randomized trial.
A second purpose is to evaluate a scheduled increase in reinforcement magnitude early in 
treatment. Reinforcement magnitude is a parameter that can increase treatment response 
(Petry et al., 2004) and may thereby increase long-term abstinence (Kenford et al., 1994; 
Higgins et al., 2006), but this has not yet been examined in a randomized clinical trial of 
treatment-seeking smokers.
The two aims of the present study are: assess the efficacy of prize-based CM for cigarette 
smoking; and compare a traditional versus early-treatment enhanced reinforcement schedule.
2. METHODS
2.1 Participants
Participants were nicotine-dependent smokers (N = 81) who responded to advertisements in 
local newspapers, bulletin boards and at health fairs, and broadcast messages to staff of a 
large health center and university. Inclusion criteria were: Fagerström Test of Nicotine 
Dependence (Heatherton et al., 1991) score ≥4; age ≥18; and English literate. Exclusion 
criteria were: uncontrolled psychiatric disorders (acute suicidality, psychosis); current 
substance dependence excluding nicotine or caffeine; in recovery for pathological gambling; 
or already receiving smoking treatment. Recruitment occurred December 2007 to January 
2011.
2.2 Procedures
Individuals were screened for eligibility and scheduled for intake if appropriate. During 
intake, written informed consent and self-report assessments and CO and urine cotinine tests 
were completed.
After Intake, participants attended the clinic twice daily (separated by 5+ hours) Monday-
Friday for 5 weeks. Unexcused absences were considered positive CO readings; excused 
absences (e.g., family emergency) were without consequences. Follow-up assessments 
occurred 2- and 6-months after starting treatment, with $20 compensation per follow-up.
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2.3 Measures
2.3.1—Demographic data were collected at intake. A brief screen of suicidality, psychosis 
and substance abuse was adapted using the Structured Clinical Interview for the DSM-IV-
TR (First et al., 2002) to assess inclusion/exclusion. Pathological gambling was assessed 
using the NORC-DSM Screen (Gerstein et al., 1999).
2.3.2—Smoking history included ages first smoked and smoked daily, and cigarettes 
smoked daily.
2.3.3—Fagerström Test for Nicotine Dependence questionnaire assessed nicotine 
dependence (Fagerstrom, 1978).
2.3.4—Expired Carbon Monoxide (CO) levels were assessed at intake, twice daily during 
baseline and treatment, and at follow-ups using an EC50-MP Micro CO monitor (Bedfont). 
Levels ≤6ppm were considered smoking-negative for reinforcement purposes, consistent 
with other studies (range: 4ppm–8ppm; Corby et al., 2000; Lamb et al., 2004).
2.3.5—Urinary Cotinine samples were collected at intake, Mondays weeks 2–5, and follow-
ups, and tested using the Accutest® NicAlertTM test-strip system (JANT Pharmacal 
Corporation, Encino, CA). During treatment weeks 2–4, cotinine samples served as a 
measure of weekend smoking abstinence (≤100ng/mL) to establish CM bonus draws.
2.4. Baseline
All participants received $1 per sample, independent of results, with a $20 bonus for 
submitting all 10 samples, to motivate compliance. Submitting ≥5 samples was required for 
randomization, else individuals were discontinued and referred for treatment elsewhere.
The baseline phase allowed for assessment of smoking pre-treatment and time to prepare to 
quit. On the last baseline visit, participants met with a research therapist to review a smoking 
cessation self-help quit guide to prepare to quit (U.S. Public Health Service, June 2000). 
Based on standards of care (Fiore et al., 2008), the materials emphasize motivation, social 
support and behavioral skills to help reduce smoking.
Random assignment to one of the three treatment conditions and stratified by gender and any 
CO ≤6 ppm during baseline (none or ≥1) occurred on treatment day 1 (quit date). 
Statistician-prepared sequentially numbered randomization envelopes concealed group 
assignments until assigned Randomization to CM conditions and standard treatment 
occurred at a 2:1 ratio to ensure adequate power to compare the two CM conditions.
2.5. Treatments
2.5.1. Standard care—Standard care (SC; weeks 2–5) involved monitoring CO and 
cotinine, and brief counseling (Fiore et al., 2008). Participants received $1/sample regardless 
of test results and a $20 weekly bonus for submitting all samples (maximum $120). Each 
session, the therapist provided immediate feedback about CO/cotinine test results, briefly 
(≈5 minutes) discussed recent smoking/abstinence, and praised quit efforts.
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2.5.2. Traditional prize CM—In addition to SC, traditional CM (TCM) patients earned 
chances to win prizes for negative CO and cotinine samples (similar to Petry and Martin, 
2002; Petry et al., 2000), with no compensation for compliance with only submitting 
samples.
On treatment day 1, participants drew for a prize if CO was reduced at least 3ppm from 
his/her intake level. Subsequently, draws were contingent on CO reading ≤6ppm. Draws 
from the prize urn increased by 1 (up to 5) each consecutive day both daily CO tests met 
criterion. CO levels >6 ppm, refusal to submit a sample, or unexcused absences reset draws 
to one for the next negative sample.
The TCM prize urn contained 250 slips of paper, with typical prize percentages (e.g., Petry 
and Martin, 2002); 50% (125) did not result in prizes, 44.8% were Small (worth about $1, 
e.g., snacks, toiletries); 4.8% were Large (worth about $20, e.g., gift certificates, 
electronics); and 0.4% were Jumbo (worth $100, e.g., DVD players, gift certificates).
To reinforce weekend abstinence, each cotinine sample ≤100 ng/ml on Mondays resulted in 
five bonus draws in weeks 3–5. Overall, 180 draws and 15 bonus draws were possible for 
CO- and cotinine-negative tests, respectively.
2.5.3. Early-treatment enhanced prize reinforcement (ECM)—ECM participants 
received SC, CO and cotinine monitoring and reinforcement criteria, described above. 
Draws available and reinforcement criteria were identical to TCM, but the chance of 
receiving reinforcement early in treatment was scheduled to be enhanced by providing 
guaranteed prizes (100% probability, versus 50% chance in TCM) for negative CO tests 
during treatment week 1.
During week 1, the ECM urn included 91.2% Small, 8% Large and 0.8% Jumbo prizes. For 
the remaining three weeks, an urn with 65.8% slips resulting in no prize, and 30% Small, 
4% Large and 0.2% Jumbo prizes was used. Draws for cotinine-negative tests were made 
from the urn with 100% winning slips, for the same overall reinforcement magnitude in both 
CM conditions.
2.6. Analysis
We employed an intent-to-treat approach, including all participants who entered the 
treatment phase. Analyses compared combined CM conditions versus SC, and TCM versus 
ECM. Chi-square and t-tests were used to analyze baseline characteristics.
Outcomes were average CO, longest duration of smoking abstinence (days; LDA), and 
percent CO tests <4ppm. The CO criterion for reinforcement was ≤6ppm to maximize 
opportunities for reinforcement, but CO <4ppm was used for analysis to ensure conservative 
reporting of findings. A day of abstinence was defined as two consecutive CO tests <4ppm. 
If sessions encompassed a weekend, the patient was considered abstinent for three 
consecutive days if tests immediately before and after the weekend were negative. 
Unexcused absences broke the string of abstinence, excused absences did not if preceded 
and followed by negative samples.
Ledgerwood et al. Page 4
Drug Alcohol Depend. Author manuscript; available in PMC 2016 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Linear mixed models were used to analyze group differences in CO levels baseline through 
treatment. Fixed factors included treatment condition, time (50 testing sessions) and the 
condition X time interaction. Cases were included as random-effects variables.
T-tests were used to assess LDA and attendance. LDA data were normalized using square-
root transformation for analysis, with raw data presented in tables to facilitate interpretation. 
Percent negative CO was the number of CO tests <4ppm divided by number of treatment 
sessions attended (maximum 40). Percent negative CO data and prize dollars earned could 
not be transformed to normality so Mann-Whitney U tests were used. Analyses were re-run 
using a cutoff of ≤6ppm (the reinforcement criterion). Although LDA and percent negative 
were predictably higher than when we used the more stringent CO <4ppm, overall direction 
and significance remained the same (available from first author).
Chi-square analysis was used for group differences at follow-ups on 7-day point prevalence 
(PPA; self-reported no smoking in the past 7 days and cotinine ≤100 ng/ml). Missing data 
were analyzed as smoking-positive.
3. RESULTS
3.1. Demographics
See Supplemental Figure 1 for participant flow and Table 1 for demographic and baseline 
data. CM participants had significantly more education than those in SC. Otherwise, 
differences were nonsignificant (ps >.05). Overall, cigarettes per day ranged from 14.7 to 
19.3 (p > .10) and average Fagerström scores revealed “moderate” nicotine dependence.
3.2. Standard Care versus CM
Baseline CO levels were similar between CM and SC (Figure 1). Linear mixed model 
analysis revealed a significant time X condition interaction, F(50,2860.37) = 2.71, p < .001, 
with CM participants reducing CO levels over time relative to SC.
CM-treated participants demonstrated significantly greater LDA than SC patients (p < .05; 
Table 1), with a medium effect size (d = .50). Percentage of negative CO tests was also 
greater with CM than SC (p < .01; Table 1).
Participants attended an average (SD) of 87.8%(16.0%) of baseline and 70.3% (28.5%) of 
treatment sessions, without differences between conditions (Table 1).
Month 2 and 6 follow-up rates were 85% and 77%, respectively, without significant 
differences between treatment conditions (ps >.10). CM and SC did not differ on PPA at 2-
month (6.3% vs. 0%; χ2(1, n = 81) = 1.12 p = .29) or 6-month follow-up (6.3% vs. 5.9%; 
χ2(1, n = 81) = .00, p = .96).
3.3. Traditional versus Early-Enhanced CM
Linear mixed model analysis comparing TCM to ECM revealed a time main effect 
(F(50,2193.12) = 25.77, p < .001), with CO levels decreasing over time regardless of 
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condition. Neither the condition main effect nor time X condition interaction was significant 
(p > .05; Figure 1).
TCM and ECM conditions did not differ significantly on LDA, percentage of CO-negative 
test or attendance (Table 1), nor PPA at 2-months (10.7% vs. 2.8%; χ2(1, n = 64) = 1.69 p 
= .19) or 6-month follow-up (10.7% vs. 2.8%; χ2(1, n = 64) = 1.69 p = .19).
3.4. Prize Earnings
Approximately 81% of CM participants earned prizes (median = $120.56). Differences in 
earnings with TCM and ECM during week-1 or across the four weeks were nonsignificant 
(Table 1).
4. DISCUSSION
Our findings demonstrate that prize CM is an efficacious smoking abstinence intervention, 
consistent with research on money/voucher CM for smoking (Ledgerwood 2008), prize CM 
for illicit substances (Petry et al., 2000; Petry et al., 2012), and Alessi et al’s (2008) pilot 
study on prize CM for smoking. We found no significant differences in outcomes between 
TCM and ECM. We thought that providing a schedule of increased chances of winning 
prizes early in treatment would result in more abstinence initiation and subsequent 
abstinence based on findings that higher magnitude of reinforcement results in better 
outcomes (Petry et al., 2004). However, our data are more consistent with studies revealing 
that start-up bonuses may not enhance CM effectiveness (Silverman et al., 1998). Indeed, 
TCM LDA and percent negative were somewhat (but nonsignificantly) higher than ECM, 
but CO levels during the week-1 enhanced period were comparable between conditions. 
Furthermore, although the TCM and ECM were scheduled to have different initial 
magnitudes, Table 1 demonstrates that in reality the early magnitude of reinforcement 
actually received did not differ between groups.
Although CM facilitated greater smoking reductions during treatment, differences were not 
apparent at follow-up. CM studies for smoking have primarily revealed no longer-term 
benefits of CM (Ledgerwood, 2008). However, it is notable that high relapse rates are also 
found for other efficacious smoking cessation interventions (Piasecki et al., 2002).
The present study has limitations. The sample size was relatively small. More importantly, 
the treatment required an intense in-person visit schedule that would be difficult to sustain in 
many populations (e.g., rural populations, low socioeconomic status).
In summary, prize CM is efficacious in promoting initial smoking abstinence among 
nicotine-dependent smokers. Research on methods to improve response rates and maintain 
abstinence is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Average twice-daily carbon monoxide levels (parts per million) for combined CM conditions 
showed significant reductions relative to baseline and relative to Standard treatment (p < .
05). Traditional and Enhanced CM conditions did not differ from each other. (Note: 
Traditional and Enhanced conditions are presented, but the combined CM condition is not, 
to enhance the readability of the graph).
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